Arcturus Therapeutics (ARCT) PT Raised to $79 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Arcturus Therapeutics (ARCT) Begins First Subject Dosing of COVID-19 STARR mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in Phase 1/2 Study
August 11, 2020 8:04 AM EDTArcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) today announced that all subjects in the first cohort have been dosed in the Phase 1/2 clinical study with its ARCT-021 investigational vaccine for COVID-19. The study is being conducted with CTI Clinical Trial and Consulting Services, a global CRO, and in collaboration with Duke-NUS Medical School in Singapore.
We are very pleased to have initiated dosing in our ARCT-021 Phase 1/2 study, and in... More
